|
CLS Cell Lines Service GmbH
pc 9s1 characteristics age Pc 9s1 Characteristics Age, supplied by CLS Cell Lines Service GmbH, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/pc-9+cells/PC-9+Cells/pmc11621501__mmc3-592-30-57 Average 94 stars, based on 1 article reviews
pc 9s1 characteristics age - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
iCell Bioscience Inc
pc9 lung cancer cells ![]() Pc9 Lung Cancer Cells, supplied by iCell Bioscience Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/pc-9+cells/pc9+lung+cancer+cells/pmc08988074-207-0-10 Average 90 stars, based on 1 article reviews
pc9 lung cancer cells - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
European Collection of Authenticated Cell Cultures
lung cancer cell line pc9 ![]() Lung Cancer Cell Line Pc9, supplied by European Collection of Authenticated Cell Cultures, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/pc-9+cells/pc9+cell+line/pmc10067399-32-5-10 Average 90 stars, based on 1 article reviews
lung cancer cell line pc9 - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Procell Inc
pc9 cell line ![]() Pc9 Cell Line, supplied by Procell Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/pc-9+cells/pc9+cell+line/pmc10859764-95-3-9 Average 90 stars, based on 1 article reviews
pc9 cell line - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Charles River Laboratories
pc9-egfr- c797s/t790m/del19 (pc9-triple-mutant) cells ![]() Pc9 Egfr C797s/T790m/Del19 (Pc9 Triple Mutant) Cells, supplied by Charles River Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/pc-9+cells/pc+9+cells++a+human+nsclc+cell+line+with+the+egfr+del19+mutation+/pmc05355811-156-0-33 Average 90 stars, based on 1 article reviews
pc9-egfr- c797s/t790m/del19 (pc9-triple-mutant) cells - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
BioResource International Inc
human lung adenocarcinoma cell lines pc-14 ![]() Human Lung Adenocarcinoma Cell Lines Pc 14, supplied by BioResource International Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/pc-9+cells/nsclc++pc9++cell+line/pmc02731142-150-1-22 Average 90 stars, based on 1 article reviews
human lung adenocarcinoma cell lines pc-14 - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
European Collection of Authenticated Cell Cultures
pc-9 cells ![]() Pc 9 Cells, supplied by European Collection of Authenticated Cell Cultures, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/pc-9+cells/pc+9+cells/pm33829270-64-4-24 Average 90 stars, based on 1 article reviews
pc-9 cells - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
China Center for Type Culture Collection
human lung adenocarcinoma cell lines pc9 ![]() Human Lung Adenocarcinoma Cell Lines Pc9, supplied by China Center for Type Culture Collection, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/pc-9+cells/human+lung+adenocarcinoma+cell+lines+pc9/pmc06791711-93-3-32 Average 90 stars, based on 1 article reviews
human lung adenocarcinoma cell lines pc9 - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Novartis
hcc827 (egfr e746_a750 del) cells ![]() Hcc827 (Egfr E746 A750 Del) Cells, supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/pc-9+cells/lung+adenocarcinoma+cells+pc+9++del+e746+a750+/pmc11566350-50-0-11 Average 90 stars, based on 1 article reviews
hcc827 (egfr e746_a750 del) cells - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
China Center for Type Culture Collection
human nsclc cell lines pc9 ![]() Human Nsclc Cell Lines Pc9, supplied by China Center for Type Culture Collection, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/pc-9+cells/human+nsclc+cell+lines+pc9/10__2147_slash_ott__s212649-39-0-13 Average 90 stars, based on 1 article reviews
human nsclc cell lines pc9 - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Shanghai Genechem Ltd
stable luc-pc-9 cells ![]() Stable Luc Pc 9 Cells, supplied by Shanghai Genechem Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/pc-9+cells/stable+luc+pc+9+cells/pmc05752879-89-0-10 Average 90 stars, based on 1 article reviews
stable luc-pc-9 cells - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Korean Cell Line Bank
human lung carcinoma cell line pc9 ![]() Human Lung Carcinoma Cell Line Pc9, supplied by Korean Cell Line Bank, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/pc-9+cells/human+lung+carcinoma+cell+line+pc9/pmc08493114-142-1-12 Average 90 stars, based on 1 article reviews
human lung carcinoma cell line pc9 - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
Image Search Results
Journal: Translational Lung Cancer Research
Article Title: The downregulation of fibrinogen-like protein 1 inhibits the proliferation of lung adenocarcinoma via regulating MYC -target genes
doi: 10.21037/tlcr-22-151
Figure Lengend Snippet: The knockdown of FGL1 and RNA-seq results. (A) The knockdown of FGL1 confirmed by western blot. (B) The knockdown of FGL1 confirmed by immunofluorescent staining. (C) Volcano map of differential gene changes in PC9 cells after FGL1 knockdown. (D) Volcano map of differential gene changes in Jurkat T cells after FGL1 knockdown. (E) The enrichment of differential genes in PC9 cells, analyzed by GSEA. **, P<0.01; ***, P<0.001. NC, negative control; KD, knockdown; LUAD, lung adenocarcinoma; FGL1, fibrinogen-like protein 1.
Article Snippet:
Techniques: Knockdown, RNA Sequencing, Western Blot, Staining, Negative Control
Journal: Translational Lung Cancer Research
Article Title: The downregulation of fibrinogen-like protein 1 inhibits the proliferation of lung adenocarcinoma via regulating MYC -target genes
doi: 10.21037/tlcr-22-151
Figure Lengend Snippet: The experiments related to cell proliferation. (A,B) Effects of FGL1 knockdown on the cycle of PC9 cells and Jurkat T cells. (C) Real-time cell analyzer presents the real-time condition of cell proliferation. (D) Colony formation confirms the cell proliferation of PC9 cells and HCC827 cells, the magnifications in the figure are 40× and 200×, respectively, both of them were stained with crystal violet. **, P<0.01; ***, P<0.001; ****, P<0.0001. NC, negative control; KD, knockdown; LUAD, lung adenocarcinoma; FGL1, fibrinogen-like protein 1.
Article Snippet:
Techniques: Knockdown, Staining, Negative Control
Journal: Cancer Science
Article Title: EGFR inhibition in EGFR ‐mutant lung cancer cells perturbs innate immune signaling pathways in the tumor microenvironment
doi: 10.1111/cas.15701
Figure Lengend Snippet: CD24 expression is induced in EGFR‐mutant NSCLC cells upon EGFR‐TKI treatment. (A) Differential gene expression between EGFR‐TKI‐treated versus ‐untreated EGFR‐mutant NSCLC cells in GSE75308 (left) and GSE57156 (right) were analyzed. (B) EGFR‐mutant PC9 and H1975 cells, and EGFR‐wild‐type RERF‐LC‐Ad1 and H522 cells were treated with osimertinib for 72 h in vitro. CD24 expression was analyzed by flow cytometry. Gray: isotype control; dotted line: untreated; line: treated. Data are representative of four independent experiments. (C) Numbers of CD24 molecules expressed on cells with or without EGFR‐TKI treatment in vitro. Data are presented as mean ± SEM from four independent experiments. Numbers of the receptors were calculated using the BD QuantiBrite kit as described in Materials and Methods. (D) CD24 gene expression in tumor cells with or without EGFR‐TKI treatment in vitro were analyzed by qRT‐PCR. Data are presented as mean ± SEM of technical replicates from at least two independent experiments. (E) EGFR‐mutant PC9 and EGFR‐wild‐type H522 cells were treated either with osimertinib, gefitinib, or afatinib for 72 h in vitro. CD24 expression was analyzed by flow cytometry. Data are representative of two independent experiments. * q < 0.01.
Article Snippet: The lung cancer cell line,
Techniques: Expressing, Mutagenesis, Gene Expression, In Vitro, Flow Cytometry, Control, Quantitative RT-PCR
Journal: Cancer Science
Article Title: EGFR inhibition in EGFR ‐mutant lung cancer cells perturbs innate immune signaling pathways in the tumor microenvironment
doi: 10.1111/cas.15701
Figure Lengend Snippet: CD24 induction in EGFR‐mutant NSCLC cells is a target of antibody‐dependent cellular phagocytosis. (A) The fraction of immune cell types in the tumor microenvironment of NSCLC from the TCGA‐LUAD dataset (B) Arbitrary gene expression levels of SIGLEC‐10 and MRC1 across macrophages in the tumor microenvironment of NSCLC (C) Siglec‐10 expression was analyzed by flow cytometry. Gray: isotype control, line: Siglec‐10. Human monocyte‐derived macrophages were differentiated according to the protocols shown in Supplementary Table . Data are a representative of at least two independent experiments from three healthy donors. (D) M‐CSF differentiated macrophages and EGFR‐TKI‐treated PC9 cells were incubated for 9 h with anti‐CD24 antibodies or isotype control antibodies. Cytochalasin D was used to inhibit macrophage phagocytosis as described in Materials and Methods. Data are presented as the mean ± SEM of technical replicates from at least two independent experiments. *** p < 0.001.
Article Snippet: The lung cancer cell line,
Techniques: Mutagenesis, Gene Expression, Expressing, Flow Cytometry, Control, Derivative Assay, Incubation
Journal: Cancer Science
Article Title: EGFR inhibition in EGFR ‐mutant lung cancer cells perturbs innate immune signaling pathways in the tumor microenvironment
doi: 10.1111/cas.15701
Figure Lengend Snippet: EGFR‐TKIs accelerate the release of the cell‐free DNA activating type I IFN response in a STING‐dependent manner. (A) EGFR‐mutant tumor cells were treated with either osimertinib (EGFR‐TKI) or paclitaxel. Data are presented as the mean ± SEM of technical triplicates from at least two independent experiments. (B) cfDNA concentrations in the supernatant were measured as described in Materials and Methods. Data are presented as the mean ± SEM of technical triplicates from at least two independent experiments. (C) THP‐1‐Dual and THP‐1‐Dual STING‐knockout (KO) cells were cultured either with LPS (500 ng/ml), IFNa2a (10,000 U/ml), tumor‐derived cfDNA (PC9 and H1975 cfDNA)/lipofectamine, or lipofectamine alone. IRF (left) and NF‐κB (right) activities were analyzed as described in Materials and Methods. (D) PMA‐differentiated THP‐1 monocytes were pretreated either with lipofectamine, poly(dA:dT) (100 ng/ml), tumor‐derived cfDNA (PC9) (100 ng/ml)/lipofectamine, or IFNa2a (20,000 U/ml) followed by IFN‐γ stimulation (100 ng/ml). (E) Expression levels of CXCL9 and CXCL10 were analyzed using flow cytometry. * p < 0.05, ** p < 0.01, **** p < 0.0001, * q < 0.01. ns, not significant.
Article Snippet: The lung cancer cell line,
Techniques: Mutagenesis, Knock-Out, Cell Culture, Derivative Assay, Expressing, Flow Cytometry
Journal: Nature Communications
Article Title: Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
doi: 10.1038/ncomms14768
Figure Lengend Snippet: IC 50 values (nM) for the mutant EGFR-expressing Ba/F3 cells, PC9 cells or MGH121 cells.
Article Snippet:
Techniques: Mutagenesis, Expressing
Journal: Nature Communications
Article Title: Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
doi: 10.1038/ncomms14768
Figure Lengend Snippet: ( a ) The results of screening the growth-inhibitory activity of 30 drugs in Ba/F3 cells expressing four types of EGFR-del19 with or without T790M or C797S mutations are shown in a heat map. Ba/F3 cells expressing each EGFR mutant were treated with 100 nM of the indicated inhibitors. After 72 h of drug treatment, the cell viability was measured using the CellTiter-Glo assay. Relative cell viability was calculated from each value divided by the DMSO control. Among the inhibitors, only brigatinib and ponatinib were sufficiently efficacious against the triple-mutant EGFR. AZD3463 acted as a weak inhibitor to the triple mutation. ( b ) Growth inhibition assessed by the CellTiter-Glo assay of EGFR-C797S/T790M/del19 (triple-del19)-mutated Ba/F3 cells treated with gefitinib, osimertinib and brigatinib.; N =3. Results are expressed as mean±s.d. IC 50 values were calculated using growth inhibition assay. ( c ) Phosphorylation of EGFR and downstream signals were significantly inhibited by brigatinib in Ba/F3 cells expressing triple-del19 even though afatinib and osimertinib did not suppress at all the EGFR signalling of triple-del19.
Article Snippet:
Techniques: Activity Assay, Expressing, Mutagenesis, Glo Assay, Control, Inhibition, Growth Inhibition Assay, Phospho-proteomics
Journal: Nature Communications
Article Title: Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
doi: 10.1038/ncomms14768
Figure Lengend Snippet: ( a ) Chemical structures of six ALK–TKIs were very similar. ( b , c ) IC 50 values in Ba/F3 cells expressing four mutation types of EGFR-del19 were obtained by treatment with brigatinib, AP26113-analog, AZD3463, TAE684, ceritinib and ASP3026 for 72 h. Those of C797S/T790M/del19 were shown by bar graph ( b ) and those of all mutation types were demonstrated by a table ( c ). The CellTiter-Glo assay was used to measure cell viability. ( d , e ) Ba/F3 cells expressing T790M/del19 ( d ) or C797S/T790M/del19 ( e ) were treated with the indicated concentrations of brigatinib, AP26113 analog, TAE684, ceritinib or ASP3026 for 6 h. Phosphorylation of EGFR and its downstream signals were evaluated by western blotting with the indicated antibodies.
Article Snippet:
Techniques: Expressing, Mutagenesis, Glo Assay, Phospho-proteomics, Western Blot
Journal: Nature Communications
Article Title: Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
doi: 10.1038/ncomms14768
Figure Lengend Snippet: ( a – e ) PC9 (del19) ( a ), PC9-T790M (T790M/del19) ( b ), PC9-triple mutant (C797S/T790M/del19) ( c ), MGH121 parent (T790M/del19) ( d ) and MGH121 resistant-2 (C797S/T790M/del19) ( e ) cells were treated with serially diluted gefitinib, osimertinib and brigatinib for 72 h. Cell viability was measured using the CellTiter-Glo assay.; N =3. Results are expressed as mean±s.d. ( f ) Western blotting of PC9 triple mutant (C797S/T790M/del19) cells indicated that brigatinib and AP26113 analog, but not afatinib or osimertinib, suppressed phosphorylation of EGFR and its downstream signalling. ( g ) Similar results were obtained in MGH121 resistant-2.
Article Snippet:
Techniques: Mutagenesis, Glo Assay, Western Blot, Phospho-proteomics
Journal: Nature Communications
Article Title: Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
doi: 10.1038/ncomms14768
Figure Lengend Snippet: ( a ) The cell growth inhibition of Ba/F3 cells expressing EGFR-C797S/T790M/del19 (EGFR-triple-del19) treated with brigatinib, AP26113-analog, AZD3463 and osimertinib at indicated concentrations combined with or without cetuximab (10 μg ml −1 ) for 72 h assessed by CellTiter-Glo assay. ( b ) Inhibition of EGFR signal pathway in BaF3 EGFR-triple-del19 cells treated with brigatinib+cetuximab (10 μg ml −1 ) for 6 h was evaluated using western blotting. ( c , d ) The cell growth inhibition of PC9 triple-mutant cells ( c ) and MGH121-res2 cells ( d ) treated with brigatinib and osimertinib at indicated concentrations combined with or without cetuximab (10 μg ml −1 ) for 72 h assessed by CellTiter-Glo assay. ( e , f ) Inhibition of EGFR signal pathway in PC9 triple-mutant cells ( e ) and MGH121-res2 cells ( f ) treated with brigatinib+cetuximab (10 μg ml −1 ) for 6 h was evaluated using western blotting.; Results in a , c , e are expressed as mean±s.d. ( N =3). The significance of difference between indicated groups are calculated by Student's t -test (NS; not significant, * P <0.05, ** P <0.01).
Article Snippet:
Techniques: Inhibition, Expressing, Glo Assay, Western Blot, Mutagenesis
Journal: Nature Communications
Article Title: Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
doi: 10.1038/ncomms14768
Figure Lengend Snippet: ( a , b ) PC9 cells expressing EGFR-C797S/T790M/del19 were subcutaneously implanted into Balb-c nu/nu mice. When the average tumour volume reached ∼200 mm 3 , the mice were randomized into vehicle control or treatment groups (50 mg kg −1 of osimertinib, 75 mg kg −1 of brigatinib, 1 mg per mouse of cetuximab three times a week or 75 mg kg −1 of brigatinib combined with cetuximab administered as previously described) and treated once daily by oral gavage for the indicated period. Tumour volume ( V ) was calculated as 0.5 × length × width 2 , and body weights (B.W.) of mice were measured twice weekly.; N =6. Results are expressed as mean±s.d. The significance of difference between the mean tumour volume of control and of brigatinib on day 7, between brigatinib and brigatinib+cetuximab on day 23, respectively, are calculated by Mann–Whitney U test (** P <0.01). ( c ) Survival periods of mice in each treatment arm were demonstrated using the Kaplan–Meier curve. ( d ) Phosphorylation of EGFR and its downstream signalling in two tumour samples obtained from each group were evaluated using western blotting. ( e , f ) In vivo experiment of PC9 triple-mutant cells following a similar protocol as in , using panitumumab 0.5 mg per mouse two times a week administered peritoneally instead of cetuximab.; N =6. Results are expressed as mean±s.d. The significance of difference between the mean tumour volume of control and of brigatinib on day 16, between brigatinib and brigatinib+panitumumab on day 23, respectively, are calculated by Mann–Whitney U test (** P <0.01). ( g ) A Kaplan–Meier curve of the survival of the mice in each treatment arm. ( h ) Phosphorylation of EGFR and its downstream signalling in two tumour samples obtained from xenografts of PC9-triple mutant cells treated for 8 days with the indicated drugs (brigatinib: 75 mg kg −1 daily, administered orally; panitumumab: 0.5 mg per mouse two times a week, administered peritoneally) were assessed by western blotting with the indicated antibodies.
Article Snippet:
Techniques: Expressing, Control, MANN-WHITNEY, Phospho-proteomics, Western Blot, In Vivo, Mutagenesis
Journal: Nature Communications
Article Title: Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
doi: 10.1038/ncomms14768
Figure Lengend Snippet: ( a , b ) MGH121-res2 expressing EGFR-C797S/T790M/del19 were subcutaneously implanted into SCID-beige mice. When the average tumour volume reached ∼200 mm 3 , the mice were randomized into vehicle control and treatment groups (50 mg kg −1 of osimertinib (po), 75 mg kg −1 of brigatinib (po), 1 mg per mouse of cetuximab two times a week and 75 mg kg −1 of brigatinib combined with cetuximab administered as previously described, respectively) and treated for the indicated period. Tumour volume ( V ) was calculated as 0.5 × length × width 2 , and the body weights (B.W.) of the mice were measured twice weekly. N =6. Results are expressed as mean±s.d. The significance in difference between the mean tumour volume of control and of osimertinib, brigatinib and cetuximab, between cetuximab and brigatinib+cetuximab, respectively, on day 42 are calculated by Mann–Whitney U test (NS: not significant, * P <0.05, ** P <0.01).
Article Snippet:
Techniques: Expressing, Control, MANN-WHITNEY
Journal:
Article Title: Tumorigenic Role of Orphan Nuclear Receptor NR0B1 in Lung Adenocarcinoma
doi: 10.2353/ajpath.2009.090010
Figure Lengend Snippet: High NR0B1 expression in SP of A549. A: Dot blot analysis of A549 cells stained with Hoechst 33342 dye in the absence (left) or presence (right) of verapamil. SP and MP cells were boxed. B: Quantitative real-time RT-PCR was performed with mRNA obtained from SP and MP of A549. The amount of NR0B1 mRNA was normalized for the amount of GAPDH mRNA. The values represent the mean ± SE of three experiments. *P < 0.01 by the Student’s t-test.
Article Snippet: The
Techniques: Expressing, Dot Blot, Staining, Quantitative RT-PCR
Journal:
Article Title: Tumorigenic Role of Orphan Nuclear Receptor NR0B1 in Lung Adenocarcinoma
doi: 10.2353/ajpath.2009.090010
Figure Lengend Snippet: Expression of apoptosis- and invasion-related genes in NR0B1-knocked down A549 cells. A: Semiquantitative RT-PCR. B: Real-time quantitative RT-PCR to examine the expression level of Bcl-2 and MMP-2. The value is shown as the mean ± SE. *P < 0.01 by the Student’s t-test.
Article Snippet: The
Techniques: Expressing, Reverse Transcription Polymerase Chain Reaction, Quantitative RT-PCR
Journal: Pharmacogenomics and Personalized Medicine
Article Title: Nuclear Pore Glycoprotein 62 Genetic Variant rs9523 is Associated with Clinical Outcomes of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Adenocarcinoma Patients
doi: 10.2147/PGPM.S329055
Figure Lengend Snippet: Functional analysis of NUP62 rs9523A>G by dual luciferase reporter assay. Renilla luciferase assay for the effect of miRNA binding on rs9523A>G using H1299 and PC9 cells. Renilla luciferase activity was normalized to firefly luciferase activity and data are presented relative to the Mock control. Each bar represents mean ± SE. P values by Student’s t -test.
Article Snippet: The
Techniques: Functional Assay, Luciferase, Reporter Assay, Binding Assay, Activity Assay, Control